Travere Therapeutics (TVTX) financial statements
Travere Therapeutics reported revenue of $491M in fiscal 2025, up 15.6% a year over 9 years.
Net income was -$26M and the operating margin -12.8%, against -43.6% in 2016.
The diluted share count rose 133% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Travere Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $134M | $155M | $164M | $175M | $198M | $132M | $109M | $145M | $233M | $491M |
| Cost of revenue | $5M | $4M | $6M | $5M | $6M | $4M | $4M | $11M | $8M | $10M |
| Gross profit | $129M | $151M | $159M | $170M | $192M | $128M | $105M | $134M | $225M | $480M |
| Research and development | $71M | $78M | $124M | $141M | $132M | $201M | $227M | $245M | $217M | $206M |
| Selling, general and admin | $92M | $101M | $104M | $129M | $136M | $126M | $198M | $266M | $264M | $337M |
| Operating income | -$58M | -$54M | -$80M | -$137M | -$176M | -$199M | -$320M | -$388M | -$324M | -$63M |
| Interest expense | $5M | $4M | $10M | $19M | $19M | $20M | $11M | $11M | $11M | $11M |
| Pre-tax income | -$58M | -$58M | -$102M | -$146M | -$189M | -$217M | -$331M | -$376M | -$321M | -$49M |
| Income tax | -$10M | $1M | $811,000 | -$21,000 | -$19M | $409,000 | $313,000 | $223,000 | $120,000 | $988,000 |
| Net income | -$48M | -$60M | -$103M | -$146M | -$169M | -$180M | -$278M | -$111M | -$322M | -$26M |
| EPS (diluted) | -$1.29 | -$1.54 | -$2.54 | -$3.46 | -$3.56 | -$3.01 | -$4.37 | -$1.50 | -$4.08 | -$0.29 |
| Diluted shares | 38M | 39M | 40M | 42M | 48M | 60M | 64M | 74M | 79M | 89M |
| Gross margin | 96.6% | 97.7% | 96.6% | 97.0% | 96.9% | 97.1% | 96.0% | 92.1% | 96.7% | 97.9% |
| Operating margin | -43.6% | -34.7% | -48.7% | -78.3% | -88.8% | -151.3% | -292.2% | -267.2% | -138.9% | -12.8% |
| Net margin | -35.9% | -38.6% | -62.5% | -83.5% | -85.4% | -136.6% | -254.4% | -76.7% | -137.9% | -5.2% |
Balance sheet
Fiscal years, from Travere Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $256M | $301M | $311M | $272M | $357M | $428M | $347M | $307M | $59M | $238M |
| Receivables | $19M | $14M | $13M | $18M | $16M | $16M | $17M | $21M | $27M | $80M |
| Inventory | $3M | $5M | $6M | $6M | $8M | $7M | $5M | $9M | $6M | $36M |
| Total current assets | $332M | $326M | $496M | $429M | $410M | $583M | $486M | $617M | $417M | $438M |
| Property, plant and equipment | $3M | $3M | $3M | $3M | $9M | $11M | $9M | $7M | $5M | $4M |
| Goodwill | $936,000 | $936,000 | $936,000 | $936,000 | $936,000 | $900,000 | $800,000 | $800,000 | $800,000 | — |
| Total assets | $525M | $520M | $709M | $605M | $607M | $777M | $673M | $789M | $594M | $605M |
| Total current liabilities | $83M | $86M | $105M | $95M | $93M | $124M | $142M | $178M | $201M | $160M |
| Total liabilities | $218M | $227M | $391M | $384M | $396M | $475M | $630M | $588M | $535M | $490M |
| Shareholders' equity | $308M | $293M | $318M | $221M | $211M | $302M | $43M | $201M | $59M | $115M |
| Net debt | -$41M | -$99M | -$103M | -$62M | -$85M | -$166M | -$62M | -$58M | -$59M | -$93M |
Cash flow
Fiscal years, from Travere Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3M | $7M | -$25M | -$58M | -$43M | -$15M | -$186M | -$280M | -$237M | $38M |
| Capital spending | $1M | $887,000 | $727,000 | $195,000 | $7M | $5M | $191,000 | $668,000 | — | — |
| Free cash flow | -$5M | $7M | -$26M | -$58M | -$50M | -$20M | -$186M | -$281M | — | — |
| Stock-based compensation | $29M | $27M | $20M | $21M | $24M | $30M | $38M | $44M | $37M | $45M |
| Share buybacks (net) | $0 | — | — | — | — | — | — | — | — | — |
| Net borrowing | $0 | $0 | -$40M | $0 | $0 | — | — | — | — | — |
| Free cash flow margin | -3.6% | 4.2% | -15.6% | -33.3% | -25.0% | -15.1% | -170.4% | -193.3% | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for TVTX.
Open TVTX in InvestinglyQuestions
What was Travere Therapeutics's revenue in 2025?
$491M in fiscal 2025, from its 10-K filing.
From Travere Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.